Ad
Search
Generic filters
Filter by content type
Taxonomy terms

ZNTL – Zentalis Pharmaceuticals Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.45

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 67.6

Low: 42

High: 120

Total Analysts: 11

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s products include ZN-c5 and ZN-c3. ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and advanced or metastatic breast cancer. The Company engaged in initiating the Phase II monotherapy and combination portions of this Phase I/II trial. ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, is being evaluated in a Phase I/II clinical trial for the treatment of advanced solid tumors as a monotherapy and in a Phase Ib clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. It uses its Integrated Discovery Engine to identify targets and develop small molecule chemical entities with properties.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses